X
[{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsius Pharma Completes Patient Enrollment in Clinical Trial of TRS01 in Patients With Non-infectious Uveitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsius Pharma Achieves Positive Results In Proof Of Concept Study For TRS01 Targeting Uveitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsier Pharma's Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for TRS01 Phase III Program in Uveitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsier Pharma Completes Successful Pre-IND Meeting with the FDA for its TRS02 Program of Back-of-the-Eye Blinding Indications","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"ISRAEL","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tarsier Pharma Raises Capital to Execute Phase-3 Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Randomized In TRS4VISION Phase-III Clinical Trial In Patients With Active Non-Infectious Anterior Uveitis Including Patients With Uveitic Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsier Pharma Announces Participation in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsier Pharma Announces Results from a Phase 3 Clinical Trial in Subjects with Noninfectious Anterior Uveitis Including Subjects with Uveitic Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsier Pharma Announces Successful Type C Meeting with FDA for TRS01 in Noninfectious Uveitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by Tarsius Pharma
Filters
Companies By Therapeutic Area
Details:
TRS01 (dazdotuftide) is a bio-inspired novel proprietary technology platform, based on a New Chemical Entity (NCE) with a disruptive mechanism of action that modulate macrophages from inflammatory macrophages (M1) to IL-10 secreting ant-inflammatory macrophages (M2).
Lead Product(s):
TRS01
Therapeutic Area: Ophthalmology
Product Name: TRS01
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 13, 2023
Details:
TRS01 (dazdotuftide) is a bio-inspired novel proprietary technology platform, based on a New Chemical Entity (NCE) with a disruptive mechanism of action that modulate macrophages from inflammatory macrophages (M1) to IL-10 secreting ant-inflammatory macrophages (M2).
Lead Product(s):
TRS01
Therapeutic Area: Ophthalmology
Product Name: TRS01
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 23, 2023
Details:
TRS01 is a potent fast-acting immunomodulator, delivered as eye drops, for the treatment of non-infectious anterior uveitis in patients with uveitic glaucoma – that is considered an end-stage condition of uveitis.
Lead Product(s):
TRS01
Therapeutic Area: Ophthalmology
Product Name: TRS01
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 08, 2022
Details:
TRS01 is a potent fast-acting immunomodulator, delivered as eye drops, for the treatment of non-infectious anterior uveitis in patients with uveitic glaucoma.
Lead Product(s):
TRS01
Therapeutic Area: Ophthalmology
Product Name: TRS01
Highest Development Status: Phase III
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 22, 2021
Details:
Following a successful End of Phase II meeting with the FDA, the Company obtained all necessary regulatory approvals to execute phase 3 for TRS01 and has recruited leading uveitis experts as principal investigators.
Lead Product(s):
TRS01
Therapeutic Area: Ophthalmology
Product Name: TRS01
Highest Development Status: Phase I/ Phase II
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Undisclosed
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Financing
August 24, 2021
Details:
In the Pre-IND meeting, Tarsier Pharma received FDA's guidance regarding the CMC requirements for slow-release formulation of TRS02. Clarity regarding bridging nonclinical studies requirements and clinical strategy were also obtained.
Lead Product(s):
TRS02
Therapeutic Area: Ophthalmology
Product Name: TRS02
Highest Development Status: IND Enabling
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 26, 2021
Details:
Company received important feedback on its trial design and program for its TRS01 Phase 3 program in uveitis, including feedback on its nonclinical and CMC plans supporting submission of a New Drug Application (NDA) in the U.S.
Lead Product(s):
TRS01 ,Adapalene
Therapeutic Area: Ophthalmology
Product Name: TRS01
Highest Development Status: Phase II
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 17, 2020
Details:
Results showed a statistically significant improvement in the signs and symptoms of the disease, with the TRS01 high-dose usage being superior to low-dose in a few important measures.
Lead Product(s):
TRS01
Therapeutic Area: Ophthalmology
Product Name: TRS01
Highest Development Status: Phase I/ Phase II
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 05, 2020
Details:
TRS01 is a Potential topical immune-modulator agent with a novel mechanism of action for treatment of ocular inflammation. This phase I/II trial is a dose ranging trial to evaluate the safety and efficacy of TRS01 in patients with anterior non-infectious active uveitis.
Lead Product(s):
TRS01
Therapeutic Area: Ophthalmology
Product Name: TRS01
Highest Development Status: Phase I/ Phase II
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 22, 2020